文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

睡眠相关低氧与COVID-19住院及死亡风险的关联:一项大型整合医疗系统研究

Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System.
PubMed 文献 · JAMA Netw Open · 2021-11-01
一句话结论在COVID-19检测人群中,睡眠相关低氧(TST<90)与SARS-CoV-2阳性无关,但感染后与住院和死亡风险升高31%相关(aHR 1.31)。

该病例对照研究在Cleveland Clinic医疗系统(俄亥俄州和佛罗里达州)纳入2020年3月8日至11月30日接受COVID-19检测且有睡眠监测记录的患者5402例,其中1935例(35.8%)SARS-CoV-2阳性。采用重叠倾向评分加权分析显示,睡眠呼吸障碍各项指标与SARS-CoV-2阳性无关;但睡眠相关低氧(TST<90)与WHO指定的COVID-19有序临床结局量表相关(aOR 1.39;95%CI 1.10-1.74;P=.005),时间事件分析显示与住院和死亡率升高31%相关(aHR 1.31;95%CI 1.08-1.57;P=.005)。提示感染后睡眠相关低氧是不良COVID-19结局的相关危险因素。

要点

  • 在5402例有睡眠监测记录的新冠检测者中,1935例(35.8%)SARS-CoV-2阳性,阳性者AHI中位数16.2 events/h高于阴性者13.6 events/h(P<.001)。
  • 阳性者TST<90中位数1.8%睡眠时间高于阴性者1.4%睡眠时间(P=.02),但重叠倾向评分加权后无SDB指标与SARS-CoV-2阳性相关。
  • 睡眠相关低氧(TST<90)与WHO COVID-19有序临床结局量表相关(aOR 1.39;95%CI 1.10-1.74;P=.005)。
  • 时间事件分析显示睡眠相关低氧与住院和死亡率升高31%相关(aHR 1.31;95%CI 1.08-1.57;P=.005)。
  • 感染SARS-CoV-2后,睡眠相关低氧是COVID-19不良结局的相关危险因素。

适用人群与场景

  • 2020年3月8日至11月30日在Cleveland Clinic医疗系统(俄亥俄州和佛罗里达州)接受COVID-19检测且有可用睡眠监测记录的患者,共5402例(平均[SD]年龄56.4[14.5]岁;3005例女性[55.6%];1696例黑人[31.4%]、3259例白人[60.3%]、822例其他种族或族裔[15.2%])。

诊断标准与关键阈值

  • 睡眠呼吸障碍由睡眠监测中呼吸暂停低通气指数(AHI)定义,依据呼吸暂停和低通气频率。
  • 睡眠相关低氧定义为总睡眠时间中血氧饱和度<90%的时间百分比(TST<90)。
  • COVID-19临床结局采用WHO指定的有序临床结局量表(住院、使用补充氧气、无创通气、机械通气或体外膜肺氧合、死亡)。

研究设计与关键结果

  • 研究类型:病例对照研究,在Cleveland Clinic医疗系统(俄亥俄州和佛罗里达州)开展,纳入2020年3月8日至11月30日接受COVID-19检测且有睡眠监测记录的患者5402例,其中1935例(35.8%)SARS-CoV-2阳性。
  • SARS-CoV-2阳性 vs 阴性患者AHI中位数16.2 events/h(IQR 6.1-39.5)vs 13.6 events/h(IQR 5.5-33.6),P<.001;TST<90中位数1.8%睡眠时间(IQR 0.10%-12.8%)vs 1.4%睡眠时间(IQR 0.10%-10.8%),P=.02。
  • 重叠倾向评分加权logistic回归后,无SDB指标与SARS-CoV-2阳性相关。
  • TST<90中位数与WHO指定的COVID-19有序临床结局量表相关(调整OR 1.39;95%CI 1.10-1.74;P=.005)。
  • 时间事件分析显示睡眠相关低氧与住院和死亡率升高31%相关(调整HR 1.31;95%CI 1.08-1.57;P=.005)。

证据类型、等级与局限

  • 证据类型:病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:睡眠呼吸障碍和睡眠相关低氧与SARS-CoV-2阳性增加无关;但一旦患者感染SARS-CoV-2,睡眠相关低氧是COVID-19不良结局的相关危险因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The influence of sleep-disordered breathing (SDB) and sleep-related hypoxemia in SARS-CoV-2 viral infection and COVID-19 outcomes remains unknown. Controversy exists regarding whether to continue treatment for SDB with positive airway pressure given concern for aerosolization with limited data to inform professional society recommendations.

OBJECTIVE: To investigate the association of SDB (identified via polysomnogram) and sleep-related hypoxia with (1) SARS-CoV-2 positivity and (2) World Health Organization (WHO)-designated COVID-19 clinical outcomes while accounting for confounding including obesity, underlying cardiopulmonary disease, cancer, and smoking history.

DESIGN, SETTING, AND PARTICIPANTS: This case-control study was conducted within the Cleveland Clinic Health System (Ohio and Florida) and included all patients who were tested for COVID-19 between March 8 and November 30, 2020, and who had an available sleep study record. Sleep indices and SARS-CoV-2 positivity were assessed with overlap propensity score weighting, and COVID-19 clinical outcomes were assessed using the institutional registry.

EXPOSURES: Sleep study-identified SDB (defined by frequency of apneas and hypopneas using the Apnea-Hypopnea Index [AHI]) and sleep-related hypoxemia (percentage of total sleep time at <90% oxygen saturation [TST <90]).

MAIN OUTCOMES AND MEASURES: Outcomes were SARS-CoV-2 infection and WHO-designated COVID-19 clinical outcomes (hospitalization, use of supplemental oxygen, noninvasive ventilation, mechanical ventilation or extracorporeal membrane oxygenation, and death).

RESULTS: Of 350 710 individuals tested for SARS-CoV-2, 5402 (mean [SD] age, 56.4 [14.5] years; 3005 women [55.6%]) had a prior sleep study, of whom 1935 (35.8%) tested positive for SARS-CoV-2. Of the 5402 participants, 1696 were Black (31.4%), 3259 were White (60.3%), and 822 were of other race or ethnicity (15.2%). Patients who were positive vs negative for SARS-CoV-2 had a higher AHI score (median, 16.2 events/h [IQR, 6.1-39.5 events/h] vs 13.6 events/h [IQR, 5.5-33.6 events/h]; P < .001) and increased TST <90 (median, 1.8% sleep time [IQR, 0.10%-12.8% sleep time] vs 1.4% sleep time [IQR, 0.10%-10.8% sleep time]; P = .02). After overlap propensity score-weighted logistic regression, no SDB measures were associated with SARS-CoV-2 positivity. Median TST <90 was associated with the WHO-designated COVID-19 ordinal clinical outcome scale (adjusted odds ratio, 1.39; 95% CI, 1.10-1.74; P = .005). Time-to-event analyses showed sleep-related hypoxia associated with a 31% higher rate of hospitalization and mortality (adjusted hazard ratio, 1.31; 95% CI, 1.08-1.57; P = .005).

CONCLUSIONS AND RELEVANCE: In this case-control study, SDB and sleep-related hypoxia were not associated with increased SARS-CoV-2 positivity; however, once patients were infected with SARS-CoV-2, sleep-related hypoxia was an associated risk factor for detrimental COVID-19 outcomes.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Pena Orbea C, Wang L, Shah V, et al. Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System. JAMA Netw Open. 2021. PMID: 34757409. doi:10.1001/jamanetworkopen.2021.34241

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。